Thrombogenicity Testing for Medical Devices: Standards, Methods, and Regulatory Evaluation

Thrombogenicity testing is an essential hemocompatibility evaluation for medical devices that contact circulating blood, including catheters, stents, vascular grafts, oxygenators, and heart valves. Conducted in accordance with ISO 10993-4 and related ASTM standards, these tests quantify thrombus formation, platelet activation, and coagulation responses to support biocompatibility demonstrations and regulatory submissions. This article explains the technical principles, sample types, test items, methodologies, and practical applications of thrombogenicity testing for medical devices.

Technical Overview

Thrombogenicity refers to the tendency of a medical device or biomaterial surface to induce thrombus (blood clot) formation upon contact with blood. When blood encounters a foreign surface, plasma proteins such as fibrinogen and von Willebrand factor adsorb rapidly onto the material, followed by platelet adhesion, platelet activation, and stimulation of the intrinsic coagulation cascade. The resulting thrombus can occlude the device lumen, release emboli into distal vessels, and lead to serious clinical consequences such as ischemia, stroke, or myocardial infarction.

ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood) is the primary standard governing thrombogenicity evaluation. The standard classifies blood-contacting devices into non-contact devices, external communicating devices (for example, catheters, cannulae, and infusion sets), and implant devices (for example, stents, grafts, and heart valve prostheses), and defines five hemocompatibility test categories: thrombosis, coagulation, platelets, hematology, and the complement system. The test strategy is selected according to the nature, duration, and flow conditions of blood contact, and typically combines validated in vitro assays with ex vivo or in vivo models where clinically justified.

Regulatory authorities worldwide, including the U.S. FDA under its ISO 10993-1 guidance, the EU Medical Device Regulation (MDR), and China's NMPA requirements referencing GB/T 16886.4 (the Chinese adoption of ISO 10993-4), expect thrombogenicity data for devices with direct circulating blood contact. Accredited third-party laboratories routinely perform these evaluations under GLP or ISO/IEC 17025 quality systems to support 510(k), PMA, CE marking, and national registration submissions.

Testing Samples

Cardiovascular and Vascular Implants

Samples include coronary and peripheral stents, stent grafts, vascular grafts, prosthetic heart valves, inferior vena cava (IVC) filters, vascular occluders, and embolic coils. These permanent or long-term implants undergo rigorous thrombogenicity assessment because surface thrombus formation directly affects device patency and embolic risk.

External Communicating Devices

This category covers central venous catheters, peripherally inserted central catheters (PICC), hemodialysis catheters, guidewires, introducer sheaths, cannulae, syringes, infusion sets, and needle-free connectors. Testing evaluates both the device surfaces themselves and any leachable effects on blood components.

Extracorporeal Blood-Contacting Devices

Membrane oxygenators for ECMO, hemodialyzers, blood tubing sets, blood pump heads, cardiotomy reservoirs, apheresis kits, and autotransfusion circuits are evaluated under dynamic flow conditions that simulate clinical extracorporeal circulation, reflecting their large blood-contacting surface areas and prolonged exposure times.

Materials, Coupons, and Coated Surfaces

For research and development purposes, testing can be performed on polymer films, metal coupons, tubing segments, textile samples, and functional coatings such as heparinized, phosphorylcholine, or hydrophilic coatings. Well-characterized negative controls (for example, medical-grade polymers with documented low thrombogenicity) and positive thrombogenic controls are tested in parallel to demonstrate assay sensitivity.

Testing Items

Thrombogenicity evaluation encompasses multiple complementary endpoints spanning the five categories defined by ISO 10993-4:

• Thrombosis endpoints: thrombus mass (gravimetric), thrombus surface coverage and scoring, percent flow reduction, occlusion rate, emboli count, and thrombus morphology by scanning electron microscopy (SEM).
• Coagulation endpoints: prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen concentration, thrombin generation, thrombin-antithrombin III complex (TAT), and prothrombin fragment F1+2.
• Platelet endpoints: platelet count and consumption, platelet adhesion density, platelet aggregation, activation markers such as P-selectin (CD62P) and PAC-1 binding measured by flow cytometry, beta-thromboglobulin, and platelet factor 4 (PF4).
• Hematology endpoints: hemolysis, leukocyte and erythrocyte counts, and leukocyte activation, typically performed in parallel with hemocompatibility hemolysis assessments per ASTM F756.
• Complement endpoints: activation products C3a, C5a, and SC5b-9, which are particularly relevant for extracorporeal circulation devices.
• Rheological endpoints: thromboelastography (TEG) or rotational thromboelastometry (ROTEM) parameters, including clotting time, clot formation kinetics, and maximum clot amplitude.

Testing Methods

In Vitro Static Contact Methods

Material samples or device segments are incubated directly with fresh human or animal blood, or with platelet-poor and platelet-rich plasma, under controlled temperature and exposure time. The in vitro plasma recalcification time method described in ASTM F2382 measures the clotting time of citrated plasma recalcified in contact with the test material, providing a sensitive screen for surface thrombogenicity.

In Vitro Dynamic Flow Methods

Dynamic models reproduce physiological shear and flow. The Chandler loop technique rotates blood-filled tubing loops to create a recirculating blood-material interface, while closed pump-driven circuits circulate blood through catheters, oxygenators, or dialyzers at defined flow rates and exposure durations. Parallel-plate and cone-and-plate flow chambers enable precise shear stress control for material screening. Common endpoints include thrombus mass, flow reduction, pressure drop, platelet consumption, and platelet activation markers.

Ex Vivo Shunt Models

Arteriovenous shunt models in animals route physiological blood flow through a test circuit containing the device, allowing evaluation under native blood, pressure, and flow conditions without full surgical implantation. These models are frequently applied to vascular grafts, oxygenators, and blood pump components.

In Vivo Implantation Models

Devices are implanted in the vasculature of appropriate animal models — commonly canine femoral or jugular veins, or porcine coronary and peripheral arteries — for a defined exposure period, ranging from short four-hour screening studies to chronic implantations of several weeks. At termination, devices are retrieved and scored for thrombus coverage using standardized 0 to 4 scales (from no visible thrombus to occlusive thrombus), weighed for thrombus mass, and examined histologically together with distal organs for evidence of embolization. Such studies are conducted under GLP conditions with institutional animal care and use committee approval.

Regardless of the model selected, results are compared statistically against negative and positive controls or a clinically established predicate device, because ISO 10993-4 does not define universal pass/fail limits.

Applications

Thrombogenicity test data support a wide range of product development and regulatory objectives:

• Regulatory submissions, including FDA 510(k) and PMA applications, EU MDR CE technical documentation, NMPA registration, and PMDA filings, as part of the overall ISO 10993-1 biological evaluation.
• Conformity with device-specific product standards, such as ISO 5840 for cardiac valve prostheses, ISO 25539-2 for vascular stents, and ISO 7199 for blood-gas exchangers.
• Research and development screening of candidate polymers, metals, and surface textures during material selection.
• Verification of antithrombotic and lubricious coatings, including heparin-immobilized and hydrophilic coatings, before and after simulated use, sterilization, or accelerated aging.
• Justification of material supplier changes, design modifications, and manufacturing process changes through comparative equivalence testing.
• Risk management documentation under ISO 14971, linking hemocompatibility hazards to verified risk control measures.

FAQ

Which medical devices require thrombogenicity testing?

ISO 10993-4 requires hemocompatibility evaluation for all devices contacting circulating blood, including external communicating devices such as catheters and infusion sets, implants such as stents and heart valves, and extracorporeal devices such as oxygenators and hemodialyzers. Devices that do not contact blood, or that contact only intact skin, generally do not require thrombogenicity testing.

How is the appropriate test method selected?

Method selection depends on the blood contact category, contact duration, flow regime, and device geometry. A risk-based rationale combining in vitro coagulation and platelet assays with dynamic flow or in vivo thrombosis models is typically documented, and regulatory reviewers expect clear scientific justification for the chosen strategy.

What blood source and anticoagulants are used?

Fresh human donor blood is preferred for coagulation and platelet function assays, while canine, porcine, ovine, or bovine blood is commonly used for dynamic and in vivo models. Citrate anticoagulation is used when coagulation times are measured, whereas heparinized blood is used in circulation models; the anticoagulant choice must not mask the endpoints being evaluated.

What are typical acceptance criteria?

There are no absolute pass/fail criteria in ISO 10993-4. Acceptance is based on comparison with validated controls or a predicate device, with typical requirements including non-occlusive thrombus, thrombus scores and mass no worse than the reference, platelet and coagulation parameter changes within predefined limits, and absence of significant embolic findings.

How long does thrombogenicity testing take?

In vitro assays can typically be completed within a few weeks. In vivo studies require several weeks to months, accounting for animal acclimatization, implantation, observation periods, and histopathological analysis. Accredited third-party laboratories can advise on protocol design, model selection, and realistic study timelines.